Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line chemotherapy for wild‐type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ct...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Yonesaka, Kimio, Denda, Tadamichi, Yamazaki, Kentaro, Moriwaki, Toshikazu, Tsuda, Masahiro, Takano, Toshimi, Okuda, Hiroyuki, Nishina, Tomohiro, Sakai, Kazuko, Nishio, Kazuto, Tokunaga, Shoji, Yamanaka, Takeharu, Boku, Narikazu, Hyodo, Ichinosuke, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198953/
https://www.ncbi.nlm.nih.gov/pubmed/27712015
http://dx.doi.org/10.1111/cas.13098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198953/
https://www.ncbi.nlm.nih.gov/pubmed/27712015
http://dx.doi.org/10.1111/cas.13098

Ejemplares similares